Merck & Co., Inc. (MRK)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Sales | 15,806 | 15,529 | 16,657 | 16,112 |
| Selling, general and administrative | 2,649 | 2,552 | 2,731 | 2,739 |
| Restructuring costs | 560 | 69 | 56 | 80 |
| Research and development | 4,048 | 3,621 | 5,862 | 3,500 |
| Other (income) expense, net | 7 | 35 | 162 | -42 |
| Cost of sales | 3,557 | 3,419 | 4,080 | 3,745 |
| Total costs, expenses and other | 10,807 | 9,626 | 12,567 | 10,106 |
| Income before taxes | 4,999 | 5,903 | 4,090 | 6,006 |
| Taxes on income | 571 | 818 | 929 | 545 |
| Net income | 4,428 | 5,085 | 3,161 | 5,461 |
| Less net income attributable to noncontrolling interests | 1 | 6 | 4 | 6 |
| Net income attributable to merck & co., inc | 4,427 | 5,079 | 3,157 | 5,455 |
| Average common shares outstanding (in shares) | 2,510,000,000 | 2,523,000,000 | 2,534,000,000 | 2,534,000,000 |
| Average common shares outstanding assuming dilution (in shares) | 2,513,000,000 | 2,531,000,000 | 2,541,000,000 | 2,544,000,000 |
| Basic earnings per common share attributable to merck & co., inc. common shareholders (in dollars per share) | 1.76 | 2.01 | 1.25 | 2.15 |
| Earnings per common share assuming dilution attributable to merck & co., inc. common shareholders (in dollars per share) | 1.76 | 2.01 | 1.24 | 2.14 |